Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI351 Plus Cetuximab β in Untreated Advanced/Metastatic KRAS G12C Mutated NSCLC
NCT07198841Phase 2Recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulzerasib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Objective Response Rate up to 2 years. Started Nov 2025; status: recruiting.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07198841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198841.